Select Your Location:

A Comparison of Tislelizumab Plus Chemotherapy vs Programmed Cell Death Protein-1 (PD-1) Inhibitor Monotherapy in First‑Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death-Ligand 1 (PD-L1) ≥50%